65 research outputs found

    Biological and morphometric aspects and rearing of Syssphinx molina (Cramer) (Lepidoptera: Saturniidae), a defoliator of parica tree.

    Get PDF
    O objetivo desse trabalho foi descrever os aspectos biológicos e morfométricos da lagarta desfolhadora do paricá, Syssphinx molina (Cramer), e fazer recomendações para a criação do inseto. O ciclo de vida foi de 62,9 dias com períodos médios para as fases de ovo, lagarta, pré-pupa e pupa de 5,6; 31,1; 2,2 e 16,6 dias, respectivamente. A viabilidade das pupas foi de 60,5% para fêmeas e 48,6% nos machos. A razão sexual foi de 0,5 e a produção média de 182,3 ± 2,2 ovos por fêmea com viabilidade de ovos de 24,3%. A longevidade média foi de 7,9 ± 2 e 8,1 ± 3 dias para fêmeas e machos, respectivamente. Outros parâmetros foram igualmente observados e comparados com a descrição de outras espécies de Saturniidae

    Effect of antibodies on the expression of Plasmodium falciparum circumsporozoite protein gene

    Get PDF
    Antibodies are known to play an important role in the control of malaria infection. However, they can modulate parasite development enhancing infection. The effect of anti-Plasmodium antibodies on the expression of circumsporozoite protein gene (csp) was investigated. Plasmodium falciparum 3D7 in vitro cultures were submitted to: i) anti- circumsporozoite protein monoclonal antibody (anti-CSP-mAb) [1μg/ml, 0.1μg/ml, 0.01μg/ml and 0.001μg/ml] and ii) purified IgG Fab fragment from a pool of malaria patients [1mg/ml and 1μg/ml]; and compared to control cultures. After 24h the number of ring infected erythrocytes was determined in order to calculate invasion efficacy. At 48h culture supernatant was collected, and the amount of circumsporozoite protein determined by ELISA, parasitaemia was calculated and cells were processed for RNA preparation. Expression of csp gene was quantified using Real time RT-PCR. There was an increase in parasite growth when treated with lower anti-CSP-mAb concentration, which was associated with lower csp expression, while 1μg/ml anti-CSP-mAb treatment presented a growth inhibitory effect accompanied by high csp expression

    A randomized trial of the close reading and creative writing program: an alternative educational method for adult group care intervention in type 2 diabetes management

    Get PDF
    Objectives: Group care for individuals with diabetes is a recognized educational practice, but techniques from narrative medicine using of literary works have never been incorporated in these programs. We designed a new educational model (i.e. the Close Reading and Creative Writing program) of group care for individuals with diabetes incorporating close reading and creative writing in group education. A randomized trial was designed to evaluate this intervention. Methods: A total of 49 individuals with type 2 diabetes, aged 6 years of school education, were randomized to 2 different group care dynamics: (a) a “control group,” with a classical structured educational approach currently used at our institution; and (b) an “intervention group,” with introduction of literary texts, narrative skills, close reading and creative writing. Evaluation included anthropometric measures, glycated hemoglobin (A1C) and questionnaires for psychological evaluation. Individual A1C levels in the 6-year period before the trial were collected from clinical records. Results: A significant reduction of A1C was observed in the intervention group, showing noninferiority in relation to the classical approach. A significant decrease in A1C was observed in relation to the 6 previous years. A significant increase in satisfaction with the therapist and group process was observed. Conclusions: This is the first randomized trial designed to evaluate a group care intervention to manage type 2 diabetes using narrative techniques. The results suggest that this may be a useful model for more highly schooled individuals, and may represent an alternative for the educational process.info:eu-repo/semantics/acceptedVersio

    Prodromal language impairment in genetic frontotemporal dementia within the GENFI cohort

    Get PDF
    Objective: To identify whether language impairment exists presymptomatically in genetic frontotemporal dementia (FTD), and if so, the key differences between the main genetic mutation groups. Methods: 682 participants from the international multicentre Genetic FTD Initiative (GENFI) study were recruited: 290 asymptomatic and 82 prodromal mutation carriers (with C9orf72, GRN, and MAPT mutations) as well as 310 mutation-negative controls. Language was assessed using items from the Progressive Aphasia Severity Scale, as well as the Boston Naming Test (BNT), modified Camel and Cactus Test (mCCT) and a category fluency task. Participants also underwent a 3 T volumetric T1-weighted MRI from which regional brain volumes within the language network were derived and compared between the groups. Results: 3% of asymptomatic (4% C9orf72, 4% GRN, 2% MAPT) and 48% of prodromal (46% C9orf72, 42% GRN, 64% MAPT) mutation carriers had impairment in at least one language symptom compared with 13% of controls. In prodromal mutation carriers significantly impaired word retrieval was seen in all three genetic groups whilst significantly impaired grammar/syntax and decreased fluency was seen only in C9orf72 and GRN mutation carriers, and impaired articulation only in the C9orf72 group. Prodromal MAPT mutation carriers had significant impairment on the category fluency task and the BNT whilst prodromal C9orf72 mutation carriers were impaired on the category fluency task only. Atrophy in the dominant perisylvian language regions differed between groups, with earlier, more widespread volume loss in C9orf72, and later focal atrophy in the temporal lobe in MAPT mutation carriers. Conclusions: Language deficits exist in the prodromal but not asymptomatic stages of genetic FTD across all three genetic groups. Improved understanding of the language phenotype prior to phenoconversion to fully symptomatic FTD will help develop outcome measures for future presymptomatic trials.</p
    corecore